Goldman Sachs analyst Salveen Richter initiated coverage of Apellis with a Buy rating and $74 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on APLS:
- Apellis Pharmaceuticals put volume heavy and directionally bearish
- SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)
- Apellis price target raised to $86 from $70 at Baird
- Apellis initiated with a Neutral at Mizuho
- Apellis price target raised to $63 from $60 at Needham